Systemic corticosteroid use and cardiovascular risk in patients hospitalized for pneumonia

Steroids. 2023 Mar:191:109161. doi: 10.1016/j.steroids.2022.109161. Epub 2022 Dec 23.

Abstract

Background: Limited data are available concerning cardiovascular risk with respect to adjunctive corticosteroid use in patients with pneumonia. We aimed to assess the associations between systemic corticosteroid use and the occurrence of major adverse cardiovascular events (MACEs) in patients hospitalized for pneumonia.

Methods: Among study participants enrolled via surveillance for severe acute respiratory infection from July 2016 to January 2017, the clinical course of patients with pneumonia was retrospectively investigated until December 2019. We evaluated the occurrence of in-hospital and after-discharge MACEs according to steroid use during hospitalization.

Results: Of the 424 patients hospitalized for pneumonia, 118 (28.8%) received systemic corticosteroids during hospitalization. The most common reason for steroid use was acute exacerbation of chronic lung disease (75.4%). Systemic steroid use was significantly associated with an increased risk of in-hospital MACEs; it was not associated with after-discharge MACEs. The risk of in-hospital MACEs was significantly greater in patients with more comorbidities, more severe pneumonia, and a higher inflammatory marker level; moreover, it was positively associated with duration and cumulative dose of steroid treatment.

Conclusion: Systemic corticosteroid use was associated with an increased risk of in-hospital MACEs in patients hospitalized for pneumonia.

Keywords: Cardiovascular event; Corticosteroid; Pneumonia.

MeSH terms

  • Adrenal Cortex Hormones* / adverse effects
  • Adrenal Cortex Hormones* / therapeutic use
  • Cardiovascular Diseases* / chemically induced
  • Cardiovascular Diseases* / epidemiology
  • Heart Disease Risk Factors*
  • Hospitalization
  • Humans
  • Pneumonia* / drug therapy
  • Retrospective Studies

Substances

  • Adrenal Cortex Hormones